Stockholm (HedgeNordic) – Immunicum, a Swedish company said to be creating the blue print for the world’s first personalized, off-the-shelf affordable cancer treatment, has decided to implement a directed issue of approximately SEK 178 million and a rights issue of approximately SEK 173 million, according to a press release.
The money to be raised is aimed at continuing to finance the clinical development of the company´s immunotherapeutical drug ilixadencel.
Several institutions are among the investors subscribing to the directed issue including three Swedish hedge fund companies; Gladiator, Nordic Cross, and Adrigo. Other institutions include AP2, AP4, and Alfred Berg.
Photo by Louis Reed on Unsplash.
